ArticleExperimental cell research2015
PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility.
Article in Experimental cell research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM).Cancers · 2024Review
- Article
- A Synopsis of Biomarkers in Glioblastoma: Past and Present.Current issues in molecular biology · 2024Review
- The regulation of cancer-associated thrombosis by podoplanin.Thrombosis update · 2024Article
- Independent effects of Src kinase and podoplanin on anchorage independent cell growth and migration.Molecular carcinogenesis · 2022Article
- Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells.Cell communication and signaling : CCS · 2022Article
- Review
- The Role of Podoplanin in Skin Diseases.International journal of molecular sciences · 2022Review
- Podoplanin: Its roles and functions in neurological diseases and brain cancers.Frontiers in pharmacology · 2022Review
- Post-translational modifications of CDK5 and their biological roles in cancer.Molecular biomedicine · 2021Review
- Effects of Maackia amurensis seed lectin (MASL) on oral squamous cell carcinoma (OSCC) gene expression and transcriptional signaling pathways.Journal of cancer research and clinical oncology · 2021Article
- Construction of Novel Methylation-Driven Gene Model and Investigation of PARVB Function in Glioblastoma.Frontiers in oncology · 2021Article
- CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis.Frontiers in immunology · 2021Article
- Review
- New Therapeutic Strategies for Osteoarthritis by Targeting Sialic Acid Receptors.Biomolecules · 2020Article
- Targeting the cyclin-dependent kinase 5 in metastatic melanoma.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Expression of podoplanin correlates with prognosis in nasopharyngeal carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2020Article
- A kinase of many talents: non-neuronal functions of CDK5 in development and disease.Open biology · 2020Review
- Podoplanin in Inflammation and Cancer.International journal of molecular sciences · 2019Review
- Functional significance of the platelet immune receptors GPVI and CLEC-2.The Journal of clinical investigation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Podoplanin (PDPN) is a transmembrane glycoprotein that promotes tumor cell migration, invasion, and cancer metastasis. In fact, PDPN expression is induced in many types of cancer. Thus, PDPN has emerged as a functionally relevant cancer biomarker and chemotherapeutic target. PDPN contains 2 intracellular serine residues that are conserved between species ranging from mouse to humans. Recent studies indicate that protein kinase A (PKA) can phosphorylate PDPN in order to inhibit cell migration. However, the number and identification of specific residues phosphorylated by PKA have not been defined. In addition, roles of other kinases that may phosphorylate PDPN to control cell migration have not been investigated. We report here that cyclin dependent kinase 5 (CDK5) can phosphorylate PDPN in addition to PKA. Moreover, results from this study indicate that PKA and CDK5 cooperate to phosphorylate PDPN on both intracellular serine residues to decrease cell motility. These results provide new insight into PDPN phosphorylation dynamics and the role of PDPN in cell motility. Understanding novel mechanisms of PDPN intracellular signaling could assist with designing novel targeted chemotherapeutic agents and procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.